MET METLIFE INC Insider Trading

EVP & Chief Risk Officer Marlene Debel sold 21,312 shares of MET at $81.59; retains 154,380 shares post-sale.

Marlene Debel, EVP & Chief Risk Officer, sold 21,312 shares at $81.59 on 2026-06-01, reducing her non-derivative holdings by 12.1% to 154,380 shares. The current price of $80.98 is -5.0% from the 52-week high of $85.29, and the stock is up 11.0% over the past 90 days. Her prior sell at this ticker on 2024-12-13 posted a 90-day return of -6.2%, consistent with her cross-ticker track record of 1 prior sells averaging -6.2% over 90 days and a 100.00% well-timed rate. The transaction removes $1,738,822.64 worth of stock from her directly-held portfolio while she retains a substantial position in the company where she serves as Chief Risk Officer.

MetLife EVP Bill Pappas sells entire 26,000 share position worth $2.1M at $80.49; complete exit signals material shift in executive's stake

EVP Bill Pappas liquidated his entire MetLife holding of 26,000 shares on 2025-05-12 at $80.49 per share, resulting in a total value of $2,092,682.80 and reducing his post-transaction holdings to 0 shares. This represents a complete exit from his equity position in the company. His prior sell at MetLife on 2024-03-18 exhibited a 90-day return of -5.2%, and his cross-ticker historical pattern shows a 90d well-timed rate of 100.00% based on 1 prior sell, suggesting a consistent track record of selling before subsequent declines. The stock is currently trading at $81.16, modestly above the execution price, though it remains 8.0% below its 52-week high of $88.25. Given that a top executive has completely eliminated his equity ownership, the timing pattern relative to his own historical behavior and the company's modest valuation (P/E 12.10) warrants investor attention to whether this reflects confidence conditions or a strategic reassessment.

Khalaf Michel, MET President & CEO, sold 20,926 shares at $82.84; stock now $81.25, down 2.5% in 30 days.

Khalaf Michel sold 20,926 shares of MetLife at $82.84 on 2024-12-13, representing a 4.0% reduction in his 521.7K share holdings. The sale occurred near the upper half of the stock's 52-week range ($65.22–$88.25), at a price 1.8% above the current $81.25 level. His prior open-market history shows 1 prior sell that registered a positive 90-day return of 6.9%, indicating the stock rose after that transaction—not a well-timed exit. At this same ticker (MET), his single prior 2024-02-05 sale likewise showed a positive 90-day return, demonstrating no pattern of well-timed sell execution on this security. The company's fundamentals show revenue of $18.4B and net income of $1.3B, though annual revenue growth is negative at -4.3%, and the valuation sits at a moderate P/E of 14.96. The transaction adds a modest data point to his MET activity but lacks a clear timing advantage relative to his historical pattern.

EVP & Chief Risk Officer DEBEL MARLENE sells 22,810 shares of MET at $82.88; retains 108,507 shares post-sale.

DEBEL MARLENE, serving as EVP & Chief Risk Officer, sold 22,810 shares at $82.88 on 2024-12-13, reducing her holding by 17.4% to 108,507 shares and generating $1,890,577.20. The sale occurred near the top of the 52-week range ($65.22–$88.25), with MET currently trading at $81.25, 7.9% below its 52-week high. At $56.3B market cap and a P/E of 14.96, MetLife is a mature financial services company; revenue declined 4.3% year-over-year in the latest reporting period. The executive retained substantial holdings post-transaction, indicating continued material ownership in the firm.